Phathom Pharmaceuticals Inc (PHAT) Stock Price, Quote & News

Company Profile

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heart...

Industry: Biotechnology

Sector: Healthcare

Phone: 877 742 8466

Website: www.phathompharma.com

Address:

100 Campus Drive, Suite 102, Florham Park, United States

AtomicAIerts Dec. 5 at 10:07 AM

$PHAT AtomicAlerts Scalp Alert Direction: SHORT Entry: $14.7 TP1: $14.0 | TP2: $13.3 | TP3: $12.6 Stop Loss: $15.3 👉 https://atomicalerts.com

0 · Reply

LiquidThetaOptions Dec. 4 at 5:56 PM

💎 LiquidTheta® Live Actionable Trade Asset: $PHAT Contracts: $PHAT January 15, 2027 $15 Calls Scale in: $6.21- $7.59 Scale out: $24.15-$41.40 Profit Potential : 128% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

Ecryder Dec. 4 at 1:48 PM

$PHAT lets have a green day!

1 · Reply

HedgeAlerts Dec. 4 at 7:10 AM

Hedge Alert Live - Protect Your Portfolio Contract: $PHAT $12.50 Put · DEC 19, 2025 Exp Entry Price: $0.50 - $1.50 Exit Price Target: $0.83 Profit Margin: +66% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Iightning Dec. 4 at 6:51 AM

1ightning® Premium Options Alert (Actionable) Ticker: $PHAT Contract: Dec 19 $12.5C Entry: 2.35 Exit: 4.15 Return: +76.73% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

BEATOFtheMARKET Dec. 2 at 7:50 PM

$PHAT $PHM $PILL $PINE $PINS Undeniable Accuracy Cycle Trading Signal plugged into AI 🔥 lists 🔥 Math don't lie 🔥

0 · Reply

Joe_90_ Dec. 2 at 4:57 PM

$PHAT watch your stops

0 · Reply

LiquidThetaOptions Dec. 2 at 2:45 PM

💎 LiquidTheta® Live Actionable Trade Asset: $PHAT Contracts: $PHAT January 15, 2027 $18 Calls Scale in: $5.31- $6.48 Scale out: $20.63-$35.37 Profit Potential : 226% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

Iightning Dec. 2 at 1:10 AM

**1ightning® Premium Options Alert (Actionable)** **Ticker:** $PHAT **Contract:** Dec 19 $17.5C **Entry:** 0.55 **Exit:** 0.86 **Return:** **+57.23% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**

0 · Reply

HedgeAlerts Dec. 1 at 10:02 PM

Hedge Alert Live - Protect Your Portfolio Contract: $PHAT $15.00 Put · DEC 19, 2025 Exp Entry Price: $1.21 - $2.20 Exit Price Target: $1.85 Profit Margin: +53% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Phathom Pharmaceuticals: Superior Efficacy Drives Vonoprazan Growth

Nov 4, 2025, 8:00 AM EST - 4 weeks ago

Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

Nov 3, 2025, 7:59 AM EST - 4 weeks ago

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Oct 30, 2025, 1:26 PM EDT - 5 weeks ago

Phathom Pharmaceuticals, Inc. (PHAT) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 7:00 AM EDT - 5 weeks ago

Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 25, 2025, 9:59 AM EDT - 5 weeks ago

Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease

Oct 23, 2025, 8:00 AM EDT - 6 weeks ago

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting

Oct 20, 2025, 8:00 AM EDT - 6 weeks ago

Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025

Oct 6, 2025, 1:29 PM EDT - 2 months ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

ABBV ALVO AMGN ARKG AZN BIIB BMY

Oct 6, 2025, 8:00 AM EDT - 2 months ago

Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer

Aug 20, 2025, 8:00 AM EDT - 3 months ago

Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder's Ownership Following Administrative Change to 13D Filing

Aug 7, 2025, 10:51 PM EDT - 4 months ago

Phathom Pharmaceuticals, Inc. (PHAT) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 10:59 AM EDT - 4 months ago

Phathom (PHAT) Q2 Revenue Jumps 441%

Aug 7, 2025, 6:59 AM EDT - 4 months ago

Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jul 28, 2025, 8:00 AM EDT - 4 months ago

Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025

Jun 25, 2025, 4:54 AM EDT - 5 months ago

Phathom Pharmaceuticals: Potential Blockbuster Gastric Acid-Reducing Drug With New Mechanism

Jun 23, 2025, 4:15 PM EDT - 5 months ago

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 23, 2025, 7:59 AM EDT - 5 months ago

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

SAGE

Jun 16, 2025, 8:00 AM EDT - 6 months ago

Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032

Jun 10, 2025, 10:08 AM EDT - 6 months ago

Tiny Phathom Pharmaceuticals Just An Got FDA Blessing And Big-Time Upside: Buy

Jun 6, 2025, 12:27 PM EDT - 6 months ago

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032

May 1, 2025, 12:09 PM EDT - 7 months ago

Phathom Pharmaceuticals, Inc. (PHAT) Q1 2025 Earnings Call Transcript

May 1, 2025, 7:00 AM EDT - 7 months ago

Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

ITCI

Apr 28, 2025, 7:59 AM EDT - 7 months ago

Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting

Apr 23, 2025, 8:00 AM EDT - 8 months ago

Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025

Apr 17, 2025, 8:00 AM EDT - 8 months ago

Frazier Life Sciences Appoints Aditya Kohli to Partner

HLVX

Apr 16, 2025, 8:00 AM EDT - 8 months ago

Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

CDTX

Apr 3, 2025, 8:00 AM EDT - 8 months ago

Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 8:00 AM EDT - 8 months ago

Phathom Pharmaceuticals Announces Leadership Succession

Mar 31, 2025, 7:59 AM EDT - 8 months ago

Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)

Mar 6, 2025, 12:13 PM EST - 9 months ago

Phathom Pharmaceuticals, Inc. (PHAT) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 8:00 AM EST - 9 months ago

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 24, 2025, 8:00 AM EST - 10 months ago

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025

Jan 29, 2025, 8:00 AM EST - 11 months ago

Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference

Dec 11, 2024, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets

Nov 10, 2024, 3:54 AM EST - 1 year ago

Phathom Pharmaceuticals, Inc. (PHAT) Q3 2024 Earnings Call Transcript

Oct 28, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024

Oct 27, 2024, 12:00 PM EDT - 1 year ago

Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting

Aug 19, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants

Aug 10, 2024, 2:52 PM EDT - 1 year ago

Phathom Pharmaceuticals, Inc. (PHAT) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 18, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults

Jun 26, 2024, 6:11 AM EDT - 1 year ago

Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays

May 11, 2024, 7:03 PM EDT - 1 year ago

Phathom Pharmaceuticals, Inc. (PHAT) Q1 2024 Earnings Call Transcript

May 9, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 3, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Mar 26, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

Mar 18, 2024, 1:19 AM EDT - 1 year ago

Phathom: Undervalued Biotech With Possible GERD Treatment Label Expansion

Mar 7, 2024, 2:11 PM EST - 1 year ago

Phathom Pharmaceuticals, Inc. (PHAT) Q4 2023 Earnings Call Transcript

AtomicAIerts Dec. 5 at 10:07 AM

$PHAT AtomicAlerts Scalp Alert Direction: SHORT Entry: $14.7 TP1: $14.0 | TP2: $13.3 | TP3: $12.6 Stop Loss: $15.3 👉 https://atomicalerts.com

0 · Reply

LiquidThetaOptions Dec. 4 at 5:56 PM

0 · Reply

Ecryder Dec. 4 at 1:48 PM

$PHAT lets have a green day!

1 · Reply

HedgeAlerts Dec. 4 at 7:10 AM

0 · Reply

Iightning Dec. 4 at 6:51 AM

1ightning® Premium Options Alert (Actionable) Ticker: $PHAT Contract: Dec 19 $12.5C Entry: 2.35 Exit: 4.15 Return: +76.73% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

BEATOFtheMARKET Dec. 2 at 7:50 PM

$PHAT $PHM $PILL $PINE $PINS Undeniable Accuracy Cycle Trading Signal plugged into AI 🔥 lists 🔥 Math don't lie 🔥

0 · Reply

Joe_90_ Dec. 2 at 4:57 PM

$PHAT watch your stops

0 · Reply

LiquidThetaOptions Dec. 2 at 2:45 PM

0 · Reply

Iightning Dec. 2 at 1:10 AM

0 · Reply

HedgeAlerts Dec. 1 at 10:02 PM

0 · Reply

Milanfinest Dec. 1 at 7:04 PM

$PHAT if we breakout is more funny

0 · Reply

StockConsultant Dec. 1 at 2:12 PM

$PHAT Phathom Pharmaceuticals stock breakout watch

0 · Reply

Morrito23 Nov. 28 at 6:11 PM

$PHAT whoaaaah! Massive volume for a half day as well.

0 · Reply

kiwitc2000 Nov. 28 at 4:30 PM

$PHAT Buy the rumor? Or heartburn?

1 · Reply

Elitealice2 Nov. 28 at 3:50 PM

$PHAT watching. My brother in law’s a doctor and he put me on this last night lol. Perks of having someone who’s a doctor in the family is that you basically get inside info on these pharma stocks.

2 · Reply

IFeelLucky812 Nov. 28 at 3:29 PM

$PHAT going to wake up one day with a PR that moves this to $35-40/share!

0 · Reply

longshot45 Nov. 28 at 3:22 PM

$PHAT 😁 When shorts realize they are on the wrong side of a trade, there are no easy shares to buy back and momentum is moving against them. Loving it!!!

0 · Reply

Joe_90_ Nov. 28 at 3:16 PM

$PHAT

1 · Reply